BioVie reports Phase 2 Long COVID drug trial results in subgroups

September 15, 2026 7:30 AM

BioVie Inc. (NASDAQ: BIVI) released topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim, an investigational oral drug, for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found